These effects are consistent with previous observations of reductive carboxylation in cells with mitochondrial defects [54], and glutamine dependence in pancreatic tumours with KRAS mutations (Fig. 4c) [9]. The gene discussed is KRAS; the disease is pancreatic neoplasm.